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Abstract The purinergic P2X7 receptor (P2X7R) has
attracted considerable interest as a potential target for various
central nervous system (CNS) pathologies including affective
and neurodegenerative disorders. To date, the distribution and
cellular localization of the P2X7R in the brain are not fully
resolved and a matter of debate mainly due to the limitations
of existing tools. However, this knowledge should be a pre-
requisite for understanding the contribution of the P2X7R to
brain disease. Here, we generated a genetic mouse model by
humanizing the P2X7R in the mouse as mammalian model
organism. We demonstrated its functionality and revealed
species-specific characteristics of the humanized receptor,
compared to the murine ortholog, regarding its receptivity to
activation and modulation by 2′,3′-O-(benzoyl-4-benzoyl)-
adenosine 5′-triphosphate (BzATP) and trifluoperazine
(TFP). This humanized P2rx7 allele is accessible to spatially
and temporally controlled Cre recombinase-mediated inacti-
vation. In contrast to previously generated knockout (KO)
mice, none of the described P2rx7 splice variants evade this
null allele. By selective disruption and assessment of human
P2RX7 expression in different brain regions and cell types, we
were able to demonstrate that the P2X7R is specifically
expressed in glutamatergic pyramidal neurons of the hippo-
campus. Also, P2X7R is expressed in major non-neuronal
lineages throughout the brain, i.e., astrocytes, oligodendro-
cytes, and microglia. In conclusion, this humanized mouse
model provides the means for detailed assessment of human
P2X7R function in vivo including evaluation of agonists or
antagonists. In addition, this conditional allele will enable fu-
ture loss-of-function studies in conjunction with mouse
models for CNS disorders.
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Introduction
P2X receptors are trimeric receptors composed of 3 subunits
that can form homo- or heteromers. Each subunit consists of
an intracellular C- and N-terminal domain as well as 2 trans-
membrane domains, joined by a cysteine-rich ectodomain that
binds adenosine triphosphate (ATP) [1, 2]. Within the P2X
family, P2X7 is the largest subunit consisting of 595 amino
acids (aa) with a unique intracellular C-terminal domain of
239 aa, which is significantly longer than in the rest of the
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family [3–5]. This long C-terminal domain comprises several
protein and lipid binding motifs as well as a cysteine-rich
domain, including a binding domain for lipopolysaccharides
(LPS) [6]. In contrast to other family members, P2X7 recep-
tors are predominantly homomers [7]. Despite the fact that
human and murine P2X7 share about 80 % sequence homolo-
gy, differences between the species have been described with
regards to receptor sensitivity toward various ligands. The hu-
man P2X7R has been shown to be 10–100 times more sensitive
to stimulation by the agonist 2′,3′-O-(benzoyl-4-benzoyl)-aden-
osine 5′-triphosphate (BzATP) compared to themurine ortholog
[4, 8, 9]. Moreover, it has been demonstrated that human and
murine receptors show different susceptibility regarding mod-
ulation of their activity by various compounds [9–11].
The human P2RX7 gene is located on chromosome 12 and
mouse P2rx7 on chromosome 5 in a region of conserved
synteny. Both genes comprise 13 exons, which give rise to
multiple splice variants. While 13 transcripts have been de-
scribed for human P2RX7, only 5 alternative transcripts have
been described for the mouse so far:P2rx7-a, P2rx7-b, P2rx7-
c, P2rx7-d, and P2rx7-k [7, 12, 13] (compare Fig. 4a). P2rx7-
b, P2rx7-c, and P2rx7-d are characterized by a truncated C-
terminus. In addition, the first exon in P2rx7-c and P2rx7-d is
affected by alternative splicing [14]. It has repeatedly been
shown that in particular, the C-terminally truncated isoforms
have a negative regulatory effect on receptor function when
co-expressed with full-length P2X7 [3, 12, 15, 16]. P2rx7-k is
characterized by an alternative exon 1, whereas exons 2–13
are identical to P2rx7-a. This isoform seemingly does not
disturb receptor function; on the contrary, it shows higher
sensitivity toward the endogenous agonist ATP. Further, it
has been shown that different to the most abundant isoform
P2rx7-a, P2rx7-k is highly sensitive to activation by extracel-
lular nicotinamide adenine dinucleotide (NAD+) via ADP-
ribosylation [17].Moreover, these 2 isoforms are differentially
expressed; P2rx7-k predominantly occurs in regulatory Tcells
whereas P2rx7-a is the dominant variant in peritoneal macro-
phages and skeletal muscle [13].
The P2X7R is broadly expressed in immune cells of the
hematopoietic lineage including monocytes, lymphocytes,
macrophages, and dendritic cells [18, 19]. Surprisingly, the
precise expression of the P2X7R in the brain is still a matter
of debate in the field [20]. In particular, neuronal expression of
the P2X7 receptor has been controversially discussed and
contested [21, 22]. The non-selectivity of available P2X7R
antibodies in the brain has been demonstrated using P2X7R
KO mouse lines generated by GlaxoSmithKline and Pfizer,
respectively [23, 24]. While the loss of P2X7R protein was
readily detected in peripheral tissues, the detection of P2X7R
in the brain in both KO lines was masked by an unknown
protein of similar size [25, 26]. This finding prevented the
reliable detection of P2X7R in the brain including more de-
tailed analyses of spatial receptor distribution in particular
brain regions, cell types, or subcellular structures. In addition,
it became clear that the KO allele of the GlaxoSmithKline
mice is not a complete null allele because splice variant
P2rx7-k evades inactivation [7, 27]. Similarly, there is evi-
dence that the Pfizer mice are still able to express a C-
terminally truncated and at least partially functional P2X7R
due to the presence of splice variants P2rx7-b and P2rx7-c
[12, 26, 28]. Thus, the protein detected in the brain of
P2X7R KO mice might represent a P2rx7 splice variant that
evades inactivation. For the most recent P2X7R KO mice,
generated by Lexicon Pharmaceuticals and the European
Conditional Mouse Mutagenesis (EUCOMM) program, re-
spectively, no information with respect to splice variants has
been provided so far [29]. Similarly, the presence of P2rx7
splice variants has not been evaluated in P2X7R knockdown
mice generated by transgenic siRNA technology [30].
The shortcomings and uncertainties in the P2X7R field
specified above are in sharp contrast to the increasing attention
the P2X7R has gained in recent years as an emerging target in
particular for CNS diseases [31, 32]. Therefore, the aim of this
work was to overcome major obstacles in P2X7R research by
providing the following: (i) an in vivo system to test the prop-
erties of human P2X7R, (ii) a mouse line that possesses a
complete null allele lacking all currently known splice vari-
ants, and (iii) a genetic tool to assist the localization of the
P2X7R in the CNS.
Materials and methods
Generation of humanized P2X7R mice
Humanized P2X7R (hP2RX7) mice were generated by knock-
in of human P2RX7 cDNA to the murine P2rx7 locus. The
homology arms of the targeting vector (amplified by PCR
from genomic DNA of TBV2 (129S2/Sv) embryonic stem
(ES) cells) enframe from 5′ to 3′: a loxP site followed by the
3′-end (1.4-kb) of mouse intron 1; the murine exon 2 is re-
placed by the human P2RX7 cDNA comprising exons 2–13; a
reverse oriented selection marker flanked by frt sites which
consists of a phosphoglycerate kinase (PGK) promoter driven
neomycin resistance gene equipped with a bovine growth hor-
mone (bGH) poly A signal (pA), a second loxP site and a
quadruple poly A signal consisting of a bGHpA, a PGK pA,
and 2 SV40 pAs. The full-length human P2X7R cDNA was
amplified by PCR from human hippocampus cDNA using
primers: forward: 5′-CAC-CAT-GCC-GGC-CTG-CTG-
CAG-CTG-CAG-TGA-TGT-TTT-3′ and reverse: 5′-GTA-
AGG-ACT-CTT-GAA-GCC-ACT-GTA-CTG-CCC-TTC-
ACT-3′ [33]. This cDNA appeared with the following amino
acid sequence at the 11 positions of previously described hap-
lotypes P2X7–1, P2X7–2, and P2X7–4: Val-76, Gly-150,
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His-155, Arg-270, Arg-276, Arg-307, Ala-348, Thr-357, Gln-
460, Glu-496, Ile-568 [34].
Mutant ES cells were used to generate chimeric mice by
blastocyst injection. Germ-line transmission of the modified
P2rx7 allele (P2rx7hP2RX7-neo) was confirmed in offspring
from male chimeras bred to wild-type C57BL/6N mice.
Finally, the frt flanked selection cassette was removed by
breeding to Deleter-Flp mice [35]. Mice with a humanized
P2rx7 allele (P2rx7hP2RX7) with conditional potential were
kept on a mixed 129S2/Sv × C57BL/6N background.
Generation of conditional P2X7R knockout mice
Conditional P2X7R KO mice were generated by breeding
hP2RX7 mice to specific Cre drivers. Heterozygous
P2rx7+/hP2RX7 Cre positive mice were either directly used
for analysis by RT-qPCR or further bred to generate
homozyogous P2rx7hP2RX7/hP2RX7 Cre positive mice, which
were used for preparation of primary cultures or in situ
hybridization.
The following Cre drivers were used: Deleter-Cre, Cre
expression driven by the ubiquitous Rosa26 promoter
(purchased from TaconicArtemis, Cologne, Germany);
Nes-Cre, Cre expression driven by nestin promoter, which
covers neurons and macroglia of the CNS [36]; Nex-Cre,
Cre expression in forebrain glutamatergic neurons [37];
Dlx5/6-Cre, Cre-mediated recombination in forebrain
GABAergic neurons [38]; Glast-CreERT2, expression of
tamoxifen-inducible Cre in astrocytes [39]; Cnp-Cre, Cre
expression in oligodendrocytes [40]; Cx3cr1-CreERT2,
expression of tamoxifen-inducible Cre in microglia [41];
En1-Cre, expression of Cre recombinase in neurons and
macroglia of the mid/hindbrain boundary [42]; Alpha6-
Cre, expression of Cre recombinase under the control of
the promoter of the GABA A receptor, subunit alpha 6 in
granule cells of the cerebellum [43]. For all experiments
involving inducible Cre recombinase lines, tamoxifen was
administered via food pellets (LAS CRdiet CreActive
TAM400, LASvendi) for 2 weeks.
Genotyping




5 ′ -GCC-AAG-CAT-TCT-ACC-AGT-TGA-GC-3 ′ ,
hP2RX7-KO-for 5′-GCA-GTC-TCT-CTT-TGC-CTC-GT-
3′, hP2RX7-KO-rev 5′-CGT-CGA-CTG-TCT-TCT-GGT-
CA-3′ resulting in a wild-type PCR product of 417 bp,
a 613 bp product for the floxed humanized allele and a
222 bp product for the KO allele.
Animals and animal housing
All mice were housed under standard laboratory conditions
and weremaintained on a 12-h light-dark cycle (lights on from
7:00 am to 7:00 pm), with food and water provided ad libitum.
All animal experiments were conducted in accordance with
the Guide for the Care and Use of Laboratory Animals of the
Government of Upper Bavaria, Germany as well as with the
Animal Care and Use Committee of the Max Planck Institute
of Psychiatry (Munich, Germany).
Primary cell culture
Primary neuronal cultures were prepared using mouse embry-
os 18 days post-coitum as previously described [44].
Astrocytic, microglial, and mixed cultures were prepared from
mice at postnatal day 2. For neuronal cultures, pregnant
mothers were sacrificed by an overdose of isoflurane and em-
bryos by decapitation; for other cultures, pups were sacrificed
by decapitation. For all cultures, the brains were dissected free
of meninges. Cortices and hippocampi were isolated together,
subsequently dissociated, and suspended in respective growth
media. Neurons were grown in neurobasal-A medium supple-
mented with B27 Supplement (Invitrogen) and GlutaMAXI
(Invitrogen). Astrocytes were grown in DMEM (Invitrogen)
supplemented with 10 % FCS and 1 % penicillin/streptomy-
cin, microglia, andmixed cultures in DMEM/F12 (Invitrogen)
also supplemented with 10 % FCS and 1 % penicillin/strepto-
mycin. To isolate astrocytes and microglia from mixed cul-
tures, cells were trypsinized when confluency was reached
until the astrocyte containing cell layer detached. To enrich
astrocytes, the floating cell layer was dissociated and trans-
ferred to a new plate [45]. For microglia-enriched cultures, the
floating cell layer was aspirated and replaced by fresh media
as previously described [46].
Reverse transcriptase quantitative real-time PCR
(RT-qPCR)
For quantification of mRNA expression levels, RNAwas iso-
lated using TRIzol (Invitrogen) and transcribed to cDNA
using the SuperScript II Reverse Transcriptase Kit
(Invitrogen) following the manufacturer protocols. Then,
qPCR was carried out in a LightCycler96 (Roche) using the
SYBR Green I Master–kit (Roche). The following primers for

















CGG-GGG-TGT-GTC-3′, LC_mouse Exon1-for 5′-CAC-









5 ′ - AGT- GCC - C TC - AAC -ATC - GAA -GTC - 3 ,
Synaptophysin-rev 5′-CGA-GGA-GGA-GTA-GTC-ACC-
AAC-3.
Analysis of splice variants
Splice variants were detected by nested RT-PCR with specific
primer combinations for the respective splice variants (Fig. 4a,
Table 1).
Calcium imaging
Cells were loaded for 45 min in darkness with Fluo-4 AM
6 μM (Molecular Probes) and Pluronic F-127 0.14 %
(Molecular Probes) in a Ca2+-buffer (125 mM NaCl, 5 mM
KCl, 0.4 mM CaCl2, 1 mM MgSO4, 5 mM NaHCO3, 1 mM
Na2HPO4, 10 mM glucose, 20 mM Hepes, pH 7.4), and then
placed on the stage of a fluorescence Olympus IX81 inverted
confocal microscope or a Tecan Genios Pro (Tecan) plate
reader. Microscope pictures were captured with the 10×
UPlanSApo (0.4 numerical aperture) objective, and cells were
plated on 8-well culture slides (Nunc Lab-Tek II Chamber
Slide/Thermo Scientific). Plate reader experiments were con-
ducted in black 96 well plates (Nunc/Thermo Scientific).
Calcium imaging data are presented as ΔF/Fo, where Fo is
the resting fluorescence (before stimulation) and ΔF is the
peak change in fluorescence from resting levels.
Yo-Pro-1-upake assay
The Yo-Pro-1-uptake assay was conducted on the plate reader
Tecan Genios Pro (Tecan). Cells were plated in black 96-well
plates (Nunc/Thermo Scientific). Prior to the experiment, cul-
ture medium was carefully aspirated, and Yo-Pro-1-assay
buffer (5 mM KCl, 0.5 mM CaCl2, 280 mM sucrose,
10 mM glucose, 10 mM hepes, pH to 7.4) with 1 μM Yo-
Pro-1 (and 3 μM TFP) was applied. Measurement was imme-
diately started, and after acquisition of a basal value, BzATP in
the respective concentration was applied.
Western blotting
For detection of P2X7 via Western blot, fresh tissue was ho-
mogenized, lysed, and subsequently analyzed by SDS-PAGE
followed by immunoblotting using antibodies against the C-
terminal domain of P2X7R (Alomone Labs, Cat no APR-004;
1:1000) and β-actin (Cell Signaling, Cat no 4967; 1:2000).
In situ hybridization
For in situ hybridization, 35S–UTP-labeled riboprobes were
hybridized on 25-μm-thick brain cryosections. The mouse-
specific P2rx7 probe comprises nucleotides 1215–1636 of
GenBank accession no. NM_011027. The human-specific
P2RX7 probe comprises nucleotides 1195–1616 of Genbank
accession no. NM_002562.
Interleukin 1β assay
Peritoneal macrophages were isolated as previously described
(Basso et al. 2009). A total of 3 μg/ml of LPS was added, and
the cells were allowed to prime for 2 h. Subsequently, the cells
were challenged with 1 mM of the P2X7R agonist BzATP for
30 min. Supernatants were collected and analyzed for inter-
leukin 1 beta (IL-1β) using an enzyme-linked immunosorbent
assay (ELISA) kit following the manufacturer’s instructions
(Endogen, Pierce Technology, Rockford, IL, USA).
Statistical analysis
Data and statistical analyses were performed with the comput-
er programs GraphPad Prism 5.0 (GraphPad software Inc., La
Jolla, CA) and SPSS 16.00 (SPSS Inc., Chicago, IL). All
results are shown as means ± standard error of the mean
(SEM). Simple comparisons were evaluated with Student’s t
test (two-tailed). Time-dependent measures were assessed
with multi-factorial analysis of variance (ANOVA) with re-
peated measures (RM-ANOVA). The effects of genotype
and/or treatment on IL-1β release and calcium uptake were
assessed by two factorial analysis of variance (two-way
ANOVA). Whenever significant main or interaction effects
were found by the ANOVAs, Bonferroni post hoc tests were
carried out to locate simple effects. Statistical significance was




Establishment of humanized P2X7R mice
To study the human P2X7 receptor (hP2X7R) in an in vivo
context, we generated a mouse line that expresses the
hP2X7R under the regulatory control of the endogenousmurine
P2rx7 locus (Fig. 1a–c). To ensure that the temporal and spatial
expression of the hP2X7R variant is indistinguishable from the
endogenous mouse P2X7R expression, we applied a knock-in
strategy substituting mouse exon 2 by the human cDNA cov-
ering exons 2–13. The correct expression of the humanized
P2X7R was confirmed by in situ hybridization in the hippo-
campus using species-specific riboprobes. In particular, the
prominent expression in the cornu ammonis subfield 3 (CA3)
was readily detectable (Fig. 1d). Moreover, this approach guar-
anteed that the expression level of the humanized P2X7R was
identical to the endogenous murine P2X7R, enabling a mean-
ingful direct comparison of murine and humanized receptors
when comparing wild-type and humanized mice.
Comparison of activities of humanized and mouse P2X7R
We compared the functional properties of the humanized and
mouse P2X7Rusing theYo-Pro-1 uptake assay, which is based
on the hallmark feature of P2X7R to form non-selective pores
upon repeated or prolonged activation. The pore formation
capacity measured by Yo-Pro-1 uptake was assessed in perito-
neal macrophages derived from wild-type and humanized
mice. Both receptor variants showed a positive correlation of
Yo-Pro-1 uptake and BzATP concentration; however, the
orthologs differed in their dynamics of Yo-Pro-1 uptake.
BzATP concentration-response curves demonstrated a ~10-
fold higher sensitivity of the humanized receptor which is ac-
tivated at significantly lower levels of the agonist BzATP com-
pared to the murine counterpart. While the murine receptor did
not elicit any pore formation below 50 μM of BzATP, the
humanized receptor induced pore formation at only 5 μM of
agonist (Fig. 2a). Additionally, we observed species-specific
differences of P2X7Rwith regards to its functional modulation
by TFP. TFP is a common antipsychotic drug of the phenothi-
azine class. Based on our dose response experiments (Fig. 2a),
we chose a BzATP concentration of 50 μM for this experi-
ment. We confirmed the earlier observed differences between
murine and humanized P2X7R with respect to Yo-Pro-1 up-
take. This difference reached statistical significance 5 min after
agonist application. Moreover, species-specific differences in
response to TFP were detected between humanized and mouse
P2X7Rs (Fig. 2b). A potentiating effect of TFP on Yo-Pro-1
uptakewas exclusively detectable for themurine but not for the
humanized P2X7R. This potentiating effect was observed
throughout the time course, starting as early as 1 min after
Table 1 RT-PCR primers used to
specifically detect different P2rx7
splice variants
Primers for first PCR Exon Code Sequence 5′→ 3′
Exon1-for 1 A CGCCCCCGCTGCAGTCACTG
Exon13-rev 13 B CGTGGAGAGATAGGGACAGCC
Exon12-for 12 E CGTTGAAGTATGTGTCCTTTGTCG
Exon13b-rev 13b F TTCTTAAATAAATGAATTGAAATCAAG
Exon4-for 4 I TGCTCTTCTGACCGGCGTTG
Exon13c-rev 13c J TCAGGTGCGCATACATACATG
Exon1c-for 1c M CACATGATCGTCTTTTCCTAC
Exon4b-rev 4b N TGACCATTCTCCTGGCTGAC
Exon1d-for 1d Q GCCCGTGAGCCACTTATGC
Exon5-rev 5 R CCTTGTCTTGTCATATGGAAC
Primers for nested PCR
Exon1-for2 1 C CCGCTGCAGTCACTGGAG
Exon13-rev2 13 D GTCGGAGAAGTCCATCTGGGGTC
Exon12-for2 12 G GCATGGTGGACCAGCAGCTGC
Exon13b-rev2 13/13b H CAGTCGTCCAGGAAGTCAGCCG
Exon9-for 9 K GAGAACAATGTGGAAAAGCGG
Exon13c-rev2 13c L CATGCAGGCAAAGCACCCGTAC
Exon2-for 2 O TGGTGAGCGATAAGCTGTAC
Exon4b-rev2 4b P CAAGTATCTGCCTCCCTTTTGAGC
Exon1d-for2 1d S GCATATGGATCGGGACGCTGAAG
Exon4-rev 4 T GGTCAGAAGAGCACTGTGC
For localization of primers, see Fig. 4a
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BzATP application (2-way RM-ANOVA: time F4,5 = 342.9,
p < 0.0001; time × genotype F4,5 = 22.6, p < 0.005; genotype
F1,8 = 28.2, p < 0.005; genotype × treatment F1,8 = 6.7,
p < 0.05; Bonferroni post hoc test, p < 0.05). Taken together,
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our findings confirm previous results showing significant
differences between human and mouse P2X7Rs with
respect to agonist-dependent activation and modulation
by pharmacological compounds.
Establishment of P2X7R knockout mice
The humanized P2rx7 locus was designed to enable Cre
recombinase-mediated inactivation of hP2X7R expression
without restoring murine P2X7R expression. To validate this
novel conditional allele, we bred humanized hP2RX7 mice to
Deleter-Cremice to generate a constitutive P2X7RKOmouse
line (Fig. 3a, b). P2X7R protein expression was absent from
the peripheral tissues of KO mice (Fig. 3c). The loss of recep-
tor activity in P2X7R KO mice was further confirmed in the
pore formation assay. Peritoneal macrophages obtained from
KO animals were no longer able to show the characteristic Yo-
Pro-1 uptake upon prolonged P2X7R stimulation. The
mouse
humanized
mouse         +  TFP (3 µM)
humanized  +  TFP (3 µM)


























































































Fig. 2 Comparison of BzATP-
induced Yo-Pro-1 uptake of
humanized and murine P2X7R
expressing peritoneal
macrophages. a Pore formation
capacity of peritoneal
macrophages expressing the
murine and the humanized
P2X7R. BzATP concentration-
response curves for the mouse
and humanized P2X7R following
different incubation times. The
humanized receptor shows higher
sensitivity toward the agonist
compared to the murine




murine or humanized P2X7R
show differential modulation of
Yo-Pro-1 uptake by TFP upon
concurrent stimulation with
BzATP. Two-way RM-
ANOVA + Bonferroni post hoc
test, *p < 0.05, **p < 0.005, n = 3
wells per group, with cells
obtained of 2 animals per
genotype. Data are expressed
mean ± SEM
Fig. 1 Generation of humanized P2RX7 (hP2RX7) mice. a Strategy for
knock-in of the human P2RX7 cDNA. Partial restrictionmaps of the wild-
type P2rx7 locus, targeting vector, mutant locus following homologous
recombination and loxP flanked (floxed) humanized locus after Flp
recombinase-mediated deletion of the selection marker (B, BamHI; pA,
polyadenylation signal). b Southern blot analysis of wild-type and
targeted ES cell clones. The 3′-probe was hybridized to BamHI-
digested genomic ES cell DNA carrying the construct for humanizaton.
The targeted allele is indicated by the presence of an additional 7.4-kb
fragment. c Genotyping was performed by PCR resulting in a 417 bp
product for the murine wild-type allele and a 613 bp product for the
humanized allele. d The expression of human P2RX7 in knock-in mice
recapitulates endogenous expression of murine P2rx7 as demonstrated by
in situ hybridization with riboprobes specific for mouse and human
transcripts, respectively. A magnification of the hippocampal CA3




response of P2X7R-deficient cells was only slightly increased
compared to untreated cells (2-way RM-ANOVA: time
F5,14 = 541.9, p < 0.0001; time × genotype F10,30 = 43.4,
p < 0.0001; time × treatment F5,14 = 523.6, p < 0.0001;
time × genotype × treatment F10,30 = 21.5, p < 0.0001; geno-
type F2,18 = 67.2, p < 0.0001; treatment F1,18 = 363.1,
p < 0.0001; genotype × treatment F2,18 = 75.2, p < 0.0001;
Bonferroni post hoc test, p < 0.05). As observed earlier, mac-
rophages expressing humanized P2X7R showed an increased
Yo-Pro-1 uptake compared to those expressing the murine
receptor (Fig. 3d). Additionally, we observed that peritoneal
macrophages of KO mice were no longer able to trigger the
Fig. 3 Generation and validation of P2X7R knockout mice. a The floxed
humanized allele allows for Cre recombinase-mediated excision of the
human P2RX7 resulting in a knockout (KO) allele. b Genotyping by PCR
discriminates between humanized (613 bp) and KO allele (222 bp). c
Representative Western blot demonstrating the loss of P2X7R protein in
peripheral tissues of KO mice (SG, salivary gland; Spl, spleen). d
Assessment of Yo-Pro-1 uptake shows that peritoneal macrophages
obtained from KO mice lost their pore formation capacity compared to
mouse or humanized cells upon prolonged stimulation of the receptor with
50 μM BzATP (two-way RM-ANOVA + Bonferroni post hoc test,
*p < 0.05, ***p < 0.0005). e Functional validation of P2X7R KO as
determined by interleukin-1β (IL-1β) release. Peritoneal macrophages of
KO mice are no longer able to secrete IL-1β in response to LPS (3 μg/ml)
stimulation and subsequent treatment with the 1 mM BzATP (two-way
ANOVA + Bonferroni post hoc test, ****p < 0.0001). f, g Functional
validation of P2X7R KO as indicated by lack of calcium uptake following
stimulation of primary brain-derived cells of KOmice with 500 μMBzATP.
fOn the level of individual cells; g on the level of an entire cell population as
determined by plate reader-based measurement (two-way ANOVA +
Bonferroni post hoc test, *p < 0.05). Moreover, KO cells do not exceed
calcium influx levels of cells treated with the purine receptor antagonist
PPADS (100 μM). Data are expressed as mean ± SEM
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release of interleukin-1β (IL-1β) in response to LPS priming
and BzATP stimulation (Fig. 3e, two-way ANOVA: genotype
F1,18 = 169.82, p < 0.0001; treatment F2,18 = 137.92,
p < 0.0001; genotype × treatment F2,18 = 139.27,
p < 0.0001; Bonferroni post hoc test, p < 0.0001). Moreover,
primary cells obtained from KO mouse brains showed a
blunted response with regard to calcium uptake measured at
the single cell level (Fig. 3f). The calcium uptake was compa-
rable to cells treated with the purinergic receptor antagonist
pyridoxalphosphate-6-azophenyl-2-4-disulfonic acid
(PPADS). This suggests that a large proportion of the
BzATP-induced calcium response is mediated by the P2X7R
and can be blocked by the non-specific P2X receptor antago-
nist PPADS (Fig. 3g, two-way ANOVA: genotype
F1,12 = 6.87, p < 0.02; treatment F1,12 = 14.05, p < 0.003;
genotype × treatment F1,12 = 9.77, p < 0.009; Bonferroni post
hoc test, p < 0.005). Finally, we assessed the presence of
P2rx7 splice variants in the KOmice. In contrast to previously
published KO mouse lines, this null allele showed absence or
functional disruption of all 5 known P2rx7 splice variants in
the brain and peripheral organs (Fig. 4). The residual tran-
scripts detected in KO mice using primers for P2rx7-a
(brain, salivary gland, and spleen) and P2rx7-b (brain) were
specified by sequencing as non-functional splice products
lacking exon 2, which is in accordance with the targeting
strategy (Fig. 3a).
P2X7R expression in different cell types of the central
nervous system
Next, we were interested in resolving the expression of
P2X7R in the murine brain. First, we prepared primary cul-
tures of different cell types derived from embryonic or early
postnatal brains (hippocampus and cortex) of humanized or
wild-type mice. Besides mixed cultures, we focused on spe-
cific neuronal, astrocytic, and microglial cultures from which
we isolated RNA (Fig. 5). The purity of the cultures was
monitored by analyzing the expression of cell type-specific
markers for neurons (synaptophysin, Syp), astrocytes (glial
fibrillary acidic protein, Gfap), and microglia (cathepsin S,
Ctss) by RT-qPCR. Mixed cultures were mainly composed
of astrocytes and microglia as indicated by the expression of
Gfap and Ctss. Analyzing the expression of P2XR family
members, we detected hP2RX7/P2rx7 expression in all culti-
vated cell types. In all cultures, P2rx4 showed the highest
expression. With the exception of P2rx1, which showed the
lowest mRNA levels in all investigated cultures, the expres-
sion level and pattern of the other family members varied
between the different isolated and cultured cell types
(Fig. 5). Taking into account that the culture conditions might
directly affect P2X7R expression in primary cells, we addi-
tionally addressed its expression in vivo.
P2X7R expression in the mouse brain
To investigate expression levels in vivo, we took advantage of
the conditional potential of our humanized P2rx7 allele and
bred hP2RX7 mice to different tissue- and cell type-specific
Cre drivers. In a first approach, we conducted in situ hybridi-
zation analyses to study P2X7R expression in more detail
(Fig. 6). On brain sections fromKOmice generated by breeding
humanized mice, toDeleter-Cremice, no mRNA of the human
P2X7R was detectable demonstrating the specificity of the
method (Fig. 6a). Of note is the loss of the faint ubiquitous
signal, which was observed throughout the brain supporting a
rather ubiquitous but weak expression of P2rx7 mRNA. The
neuron- and macroglia-specific Nes-Cre driver deleted the
hP2RX7 signal in the entire brain including the prominent sig-
nal in the CA3 of the hippocampus (Fig. 6b). By using the
excitatory neuron-specific Nex-Cre driver, we confined the sig-
nal in the CA3 to neurons and even more specifically to excit-
atory, i.e., glutamatergic neurons (Fig. 6c). The En1-Cre driver,
in which Cre recombinase is exclusively expressed in the mid-
hindbrain area, enabled us to address the expression of P2X7R
in neurons and macroglia in this brain region. As expected,
hP2RX7 expression was not affected in forebrain regions like
the hippocampus (Fig. 6d). However, we observed strong dif-
ferences in the hindbrain where the signal for hP2RX7 was
reduced in all regions of the cerebellum (Fig. 6f).
In situ hybridization is not informative in structures and cell
types with low levels of P2X7R expression. Therefore, to gain a
deeper understanding of where and to what extent P2X7R is
expressed in the mouse brain, we conducted RT-qPCR analyses.
To this end, we used heterozygous humanized mice carrying 1
wild-type and 1 conditional humanized P2rx7 allele that were
bred to different cell type-specific Cre drivers. We chose hetero-
zygousmice in order to enable a normalization of the expression
of the humanized P2RX7 to the mouse P2rx7 allele, which is
insensitive to Cre recombinase-mediated inactivation. The ex-
pression of hP2RX7 for each of the three investigated tissues
(cortex, hippocampus, and cerebellum) in heterozygous human-
ized mice without Cre recombinase (P2rx7+/hP2RX7) was set at
100 %. As shown before, the hP2RX7 expression in heterozy-
gous KO mice (P2rx7+/−) was completely abolished or below
the detection level (Fig. 7).
In Nes-Cre positive mice, the hP2RX7 expression levels
were decreased to 10–20 % in all investigated brain regions
compared to P2rx7+/hP2RX7 mice (t test: Ctx, t4 = 17.62,
p < 0.0001; Hip, t4 = 10.65, p = 0.0004; Cb, t4 = 11.14,
p = 0.0004). Since recombination inNes-Cremice, the recom-
bination occurs in both neuronal and macroglial lineages but
not in microglia; we additionally usedCx3cr1-CreERT2mice,
which express Cre recombinase in the brain exclusively in
microglia [47]. The Cx3cr1-CreERT2 positive mice showed
a 15–20% reduction of hP2RX7 expression in the brain (t test:
Ctx, t4 = 4.76, p = 0.009; Hip, t4 = 2.14, p = 0.09; Cb, t4 = 1.9,
Purinergic Signalling
p = 0.13). In line with the fact that Nes-Cre and Cx3cr1-
CreERT2 together cover almost all cell types found in the
brain (with some exception, e.g., blood cells and cells forming
the blood vessels), the combination of hP2RX7 expression
detected in both lines reached approximately 100 %.
To study the neuronal P2RX7 expression in more detail, we
used the Nex-Cre driver, which is specific for glutamatergic
neurons. Nex-Cre positive mice showed the strongest reduc-
tion in P2RX7 expression in the hippocampus (t test: Ctx,
t4 = 0.9, p = 0.38; hip, t4 = 3.86, p = 0.012; Cb, t4 = 1.3,
p = 0.25), which is in line with the in situ hybridization result.
The remaining expression originates from other cell types
which are also responsible for the overall weak in situ hybrid-
ization signal still present in Nex-Cre positive mice (Fig. 6c).
A minor reduction in the cerebellum might originate from the
partial recombination in deep nuclei and in the granule cell
layer reported for this line [37]. In the cortex, no alteration in
hP2RX7 was observed. To cover almost all neurons, we in-
cluded Dlx5/6-Cre mice, which exclusively recombine in
GABAergic neurons (data not shown). However, combined
recombination in excitatory and inhibitory neurons did not
reduce hP2RX7 expression any further (t test: Ctx,
t4 = 0.4, p = 0.7; hip, t4 = 2.3, p = 0.09; Cb, t4 = 1.44,
p = 0.22; Fig. 7).
Utilizing the Glast-CreERT2 driver, we could detect a sub-
stantial amount of hP2RX7 expression in astrocytes in all an-
alyzed brain regions (t test: Ctx, t4 = 6.86, p = 0.002; hip,
t4 = 3.9, p = 0.018; Cb, t4 = 5.53, p = 0.005). Expression in
oligodendrocytes was even higher, as revealed by the use of
the oligodendrocyte-specific Cnp-Cre driver (t test: Ctx,
Fig. 4 Assessment of P2rx7 splice variants in P2X7R knockout mice. a
Depicted are the 5 described P2rx7 splice variants. Exons differing from
the most abundant variant P2rx7-a are highlighted in blue. Translation
start and stop sites are indicated by asterisks. Exon sizes are true to scale.
Primers used for nested RT-PCR are schematically depicted above and
below each transcript and are indicated by capital letters and arrows. b
P2X7R knockout (KO) mice lack all P2rx7 splice variants as determined
by PCR. The remaining amplicons lack exon 2 and therefore do not
represent transcripts translated to functional proteins
Fig. 5 Expression of P2X receptor family members in different brain-
derived primary cells. Relative mRNA expression levels of P2X receptor
family members assessed in a mixed, b neuronal, c astrocytic, and d
microglia primary cultures. The composition and purity of each culture
were determined by the expression levels of cell type-specific markers
(right panels). Humanized P2RX7 mice were used for preparation of
cultures except in d were wild-type mice were used instead. For each
culture, hP2RX7/P2rx7 acts as reference and is set to 1. For the graphs
of the markers of the respective cell types (right panel), the highest





t4 = 10.57, p = 0.0005; hip, t4 = 7.5, p = 0.0017; Cb, t4 = 8.2,
p = 0.0012). Moreover, we could confirm the results from the
in situ hybridization with respect to the expression of hP2X7R
in the cerebellum by using the En1-Cre mice (t test: Ctx,
t4 = 0.76, p = 0.49; hip, t4 = 0.84, p = 0.45; Cb, t4 = 10.64,
p = 0.0004). Finally, the utilization of the Alpha6-Cre driver
line excluded the possibility that P2X7R is expressed in gran-
ule cells—one of the main cell types in the cerebellum (t test:
Ctx, t4 = 0.91, p = 0.41; hip, t4 = 0.033, p = 0.97; Cb,
t4 = 0.70, p = 0.52).
Discussion
The P2X7 receptor is a ligand-gated cation channel, which
plays an important role in different physiological and patho-
physiological processes. Alterations in receptor function
caused by non-synonymous single nucleotide polymorphisms
(SNPs) in the human P2RX7 gene have been associated with
various diseases including bone disorders, infectious disease,
inflammatory and cardiovascular disorder, malignancies, and
psychiatric disorders [48, 49]. The majority of non-
synonymous SNPs are either loss- or gain-of-function
mutations [50]. However, also primarily neutral polymor-
phisms might cause alterations in receptor activity, as we re-
cently showed that co-expression of the neutral Gln460Arg
polymorphism impairs P2X7R function when co-expressed
with the wild-type variant [33]. Due to its involvement in
health and disease, the P2X7R became an emergent target
for the development of selective antagonists or modulators.
Some of the oldest and still used antagonists are Brilliant
Blue G (BBG) and PPADS [51, 52]. However, they were
shown to lack full selectivity: BBG inhibits other receptors,
e.g., pannexin 1 [53] whereas PPADS is able to affect other
P2X receptor family members [54]. In recent years, novel and
more specific P2X7R antagonists have been developed, and
some have entered clinical trials [32, 55, 56]. Nevertheless, the
in vivo characterization and evaluation of their therapeutic
potential are mostly still pending. The well-known species-
specific differences with regards to receptor sensitivity to ag-
onists, antagonists, and modulators are complicating in vivo
testing. Therefore, we generated a mouse model that expresses
a humanized P2X7R under the control of the endogenous
murine regulatory elements enabling the interrogation of the
properties of the human P2X7R in vivo.We deliberately chose
a strategy, which leaves the 5′ end of the murine P2rx7 gene,
including exon and intron 1, unaffected to ensure that the
humanized receptor is expressed identically to the mouse
P2X7R. This is fundamental prerequisite for the purposed
determination of P2X7R expression in the mouse brain. Due
to this strategy, we generated a chimeric P2X7R in which the
vast majority of the receptor (553 aa) is of human origin while
the first 42 aa are derived frommouse exon 1. Exon 1 encodes
the intracellular N-terminus (30 aa), and the initial 12 aa of the
first transmembrane domain. From the 11 aa that differ
Fig. 7 Analysis of P2X7R expression in themouse brain byRT-qPCRusing
conditional knockout mice. Relative expression of hP2RX7 was determined
by real-timeRT-qPCRusingmRNAprepared from cortex, hippocampus, and
cerebellum of heterozygous humanized mice (P2rx7+/hP2RX7; +/hP2RX7).
Expression of the floxed human P2RX7 transcript was normalized to the
expression of the endogenous murine P2rx7 transcript (≙100 %).
Heterozygous knockout mice demonstrated the specificity of the RT-qPCR.
Cortex, hippocampus, and cerebellumof heterozygousmice positive for brain
region- or cell type-specifically expressed Cre recombinase were analyzed
accordingly. t test, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001;
significant effect compared to +/hP2RX7 for the respective brain region. T
p < 0.1. Data are expressed as mean ± SEM (n = 3)
Fig. 6 Analysis of P2X7R expression in the mouse brain by in situ
hybridization using human- and mouse-specific riboprobes on condition-
al knockout mice. Depicted are coronal brain sections (overview, left
columns) and magnifications (hippocampus or cerebellum, right
columns) of control mice (−Cre) and respective conditional knockout
mice generated by breeding to a Deleter-Cre, b Nes-Cre, c Nex-Cre,
and d, e En1-cremice (+Cre).White arrows indicate in situ hybridization
signals in the white matter of the corpus callosum (a) and cerebellum (e)
R
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between human and mouse, there are 9 conservative substitu-
tions. To the best of our knowledge, the two non-conservative
substitutions in the intracellular domain (Trp-7-Cys and Thr-
24-Met) as well as the conserved substitutions have not been
demonstrated to affect receptor properties. Therefore, this
mouse line is an animal model ideally suited to evaluate the
properties of novel compounds targeting the human P2X7R
including their therapeutic potential in vivo.
We used the Yo-Pro-1 uptake assay as a well-established
readout for the assessment of P2X7R sensitivity toward dif-
ferent agonists and antagonists as well as for the comparison
of receptor orthologs from different species [8, 9, 11]. All
previous studies investigating inter-species differences of
P2X7R orthologs were conducted in heterologously express-
ing cell lines. Here, we compared the Yo-Pro-1 uptake capac-
ity of murine and humanized P2X7R endogenously expressed
in primary cells obtained from respective mice. The detected
difference in Yo-Pro-1 uptake between humanized and mouse
P2X7R was comparable to previous reports [8]. To activate
the pore formation via the murine P2X7R to levels compara-
ble with the human P2X7R ~10 times higher BzATP concen-
trations were required. These observations indicate that the
chimeric humanized P2X7R behaves largely similar com-
pared to the pure human P2X7R. Nevertheless, further com-
prehensive testing is required to fully exclude differences in
their properties. In addition, we observed that the modulator
TFP had a potentiating effect on Yo-Pro-1 uptake exclusively
on the murine receptor but not on the humanized P2X7R.
Species-specific effects of positive and negative modulators
have repeatedly been described for P2X7R orthologs [8, 10,
57, 58]. These findings suggest that our humanized mouse
model is well-suited to discriminate properties of mouse and
human P2X7R orthologs in an in vivo context and thereby
opens new possibilities for the screening and evaluation of
new P2X7R agonists and antagonists.
In addition, the humanized allele was designed to allow for
Cre recombinase-mediated inactivation of the P2X7R. To
date, 3 different P2X7R KO mouse lines and 1 knockdown
line have been described [23, 24, 29, 30]. However, these lines
have been shown to be flawed. In particular, the KO strategies
applied in the lines from Pfizer [23] and GlaxoSmithKline
[24] permit some splice variants evade inactivation [7, 12,
26–28]. Our novel KO line showed complete loss of receptor
function by different readouts includingWestern blot, Yo-Pro-
1 uptake, release of IL-1β, and uptake of Ca2+. Moreover, we
specifically investigated the 5 known P2rx7 splice variants
and were able to demonstrate either their complete absence
or their functional disruption. Thus, we believe that this con-
ditional humanized allele shows a greater potential compared
to previously generated KO alleles. To date, it is unclear to
what extent the known phenotypes observed in existing KO
mice are affected by the presence of residualP2rx7 transcripts.
Our novel KO allele provides the opportunity to critically
reevaluate described phenotypes in a fully P2X7R negative
background.
We used the mouse line expressing the human P2RX7 tran-
script (exons 2–13) from the murine P2rx7 locus as a sensitive
reporter to address the controversially debated expression of
P2X7R in the CNS [20, 31]. In a first step, we compared the
mRNA expression of P2X receptor family members in primary
cultures. We found that in all cases, P2rx4 surmounts the other
family members with regards to expression levels. The smallest
difference between P2rx4 and P2rx7 expression was detected in
neurons with around a 2-fold higher expression of P2rx4. In
astrocytes and microglia, the difference is about 18-fold. This
is an important finding considering that among all P2X family
members, P2X4R is the closest relative of P2X7R [15]. Along
these lines, the genes for both family members are located in
close vicinity just 20–25 kb apart on human chromosome 12
and mouse chromosome 5, respectively. Moreover, P2X4R is
up to 10 times more sensitive to the ligands ATP and BzATP
than P2X7R [59]. It was further proposed that co-expressed
P2X4 and P2X7 can form functional heteromers, although this
finding has not been confirmed in more recent studies [60, 61].
Most importantly, however, is the finding that in vitro P2X7R is
expressed in 3 of the main cell types of the brain: microglia,
astrocytes, and neurons. Nevertheless, the expression of other
family members, in particular P2X4R, has to be considered
critically for functional analyses of the P2X7R in vivo.
Furthermore, we took advantage of the vulnerability of the
humanized P2rx7 allele to Cre recombinase-mediated inacti-
vation. By breeding humanized mice to Cre driver mice,
P2X7R expression was ablated in a region- or cell type-
specific manner. Analysis of hP2RX7 expression by in situ
hybridization using a human-specific riboprobe revealedwith-
in the brain the hippocampal CA3 region as the most promi-
nent expression domain. Expression in the CA3 subfield was
further specified and specifically localized to soma of gluta-
matergic pyramidal neurons. Interestingly, the expression out-
side of the CA3 area is rather uniform but weak. Only the
utilization of Deleter- and Nes-Cre mouse lines allowed us
to ascertain that this is indeed a P2X7R-specific signal.
Interestingly, the faint signal in Nes-Cremice is slightly stron-
ger than in Deleter-Cre mice providing some evidence for
P2X7R expression in microglia, which have a different devel-
opmental origin than neurons or macroglia, and thus are not
covered by the Nes-Cre driver. The RT-qPCR analysis clearly
demonstrates expression of hP2RX7 in the cortex and cerebel-
lum, i.e., structures of low expression as detected by in situ
hybridization. Using specific Cre drivers for astrocytes (Glast-
CreERT2), oligodendrocytes (Cnp-Cre), and microglia
(Cx3cr1-CreERT2) suggests that these cell populations are
the sources for the low ubiquitous expression. Some more
specific staining can be allocated to the white matter, e.g., in
the corpus callosum and cerebellum that is probably related to
oligodendrocytes. The RT-qPCR readily confirmed the
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expression of P2X7R in these main non-neuronal lineages of
the CNS. The expression in astrocytes, oligodendrocytes, and
microglia is in accordance with previous reports (reviewed in:
[31]). However, this study demonstrates for the first time
mRNA expression in all major cell lineages of the brain in a
paralleled approach using mouse genetic tools thus avoiding
any alterations in expression due to isolation and cultivation of
primary cells. Based on the sensitivity of the method, we have
strong evidence that neuronal expression is exclusively re-
stricted to the hippocampal CA3 region. In the cortex and
cerebellum of Nex-Cre, Dlx-Cre, and Alpha6-Cre positive
mice, no reduction in hP2RX7 was observed, arguing against
neuronal P2X7R expression in these structures. Nevertheless,
it cannot be fully ruled out that conditions exist that might
induce P2X7R expression in neurons outside the hippocampus
as it has been demonstrated for astrocytes and microglia [62].
In addition, the sensitivity of the applied methods has to be
taken into account which might overlook low levels of P2X7R
expression. Finally, it remains to be tested to what extent these
results are transferable to the human brain considering that the
transcriptional regulation might be different. In conclusion, our
analyses at the mRNA level demonstrate that the P2X7R under
basal conditions is rather ubiquitously expressed throughout
major non-neuronal cell types of the mouse brain including
astrocytes, oligodendrocytes, and microglia. A comparative
quantification of P2X7R expression in these cell types is rather
difficult since the actual contribution of each cell type to the
total P2X7R expression depends on the numeric proportion of
the respective cell type and the level of P2X7R expression
therein. We unequivocally verified that P2X7R expression is
restricted to glutamatergic neurons within the hippocampal
CA3 region albeit with mRNA levels higher than in any other
cell type of the brain as indicated by in situ hybridization.
Other means to interrogate the expression of a gene of
interest are reporter and Cre mice [63]. P2rx7-EGFP reporter
mice (Tg(P2rx7-EGFP)FY174Gsat) have been generated by
the Gene Expression Nervous System Atlas (GENSAT) pro-
ject (http://www.gensat.org/). These mice have been used to
co-localize P2X7R-expressing cells in the brain with the tran-
scription factor Sp1 [64]. In addition, this reporter line has
been used to monitor P2X7R expression following a chal-
lenge such as status epileptics, which promotes enhanced
green fluorescent protein (EGFP) expression in granule cells
of the dentate gyrus [65] or conditions of ischemic tolerance,
which induce expression of EGFP in microglia and activated
astrocytes of P2rx7-EGFP mice [66]. The assumption that
EGFP is reflecting endogenous expression is primarily based
on the observed EGFP expression in macrophages and in the
spleen—2 major sites of P2X7R expression [64]. In this con-
text, it is of note that the strong expression at the mRNA level
in the CA3 is not reflected by EGFP expression in this reporter
mouse line (compare: http://www.gensat.org/). Recent reports
on the variability even of bacterial artificial chromosome
(BAC)-based transgenic mouse lines [67, 68] underscore the
need for a more careful evaluation of the P2rx7-EGFP
reporter line. Similarly, the KO allele generated by
GlaxoSmithKline includes a LacZ reporter gene [24].
However, LacZ-staining of tissue sections of these mice re-
vealed only staining in the ependymal cell layer and of cells in
the submandibular gland [25]. Similarly, LacZ-staining of
brain sections from P2rx7 KO mice (P2rx7tm1a(EUCOMM)Wtsi)
generated by the EUCOMM program, which harbor a LacZ
reporter cassette, did not reveal any staining (data not shown)
supporting the generally low expression observed by in situ
hybridization. In contrast to these single copy reporters, which
were inserted in the endogenous gene locus, transgenic re-
porters harboring several copies of the construct might possess
higher expression levels explaining the observations in P2rx7-
EGFP mice. Alternatively, a P2rx7-specific Cre driver would
provide the highest sensitivity and ultimately unravel the com-
plexity of the P2X7R expression space. However, none of
these reporter mice provide any information with respect to
the subcellular localization of the receptor. Thus, mice ex-
pressing a P2X7R fused to a fluorescent reporter or equipped
with a tag would be important to address its currently largely
speculative subcellular localization in greater detail.
Taken together, in the present study, we established for the
first time an animal model that enables the functional interroga-
tion of the human P2X7R in the context of a mammalian model
organism. We used this humanized mouse line to assess P2X7R
expression and ultimately determined its distribution throughout
the mouse brain and its main cell lineages. Moreover, this hu-
manized mouse line provides a conditional allele that is sensitive
to Cre recombinase-mediated inactivation. This null allele is su-
perior to previously described KO alleles as it lacks any receptor
activity and all known splice variants. Thus, this novelmultifunc-
tional allele provides the means to test compounds targeting the
P2X7R under in vivo conditions and to address its function by
more precise approaches since it avoids compensatory mecha-
nisms and other caveats accompanying constitutive KO mice.
Finally, taking into account the species-specific differences with
respect to receptor sensitivity toward ligands, this humanized
P2X7R mouse line could serve as an appropriate Bwild-type^
control for the in vivo interrogation of the numerous disease-
associated non-synonymous SNPs in the human P2X7R.
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